Valuation : Celldex Therapeutics, Inc.

Market Cap 3.07B 2.64B 2.49B 2.27B 4.24B 292B 4.26B 29.5B 11.4B 149B 11.54B 11.28B 472B P/E 2026 *
-9.32x
P/E 2027 * -9.23x
Enterprise Value 2.41B 2.07B 1.95B 1.78B 3.33B 229B 3.34B 23.14B 8.94B 117B 9.05B 8.85B 370B EV / Sales 2026 *
1,186x
EV / Sales 2027 * 191x
Free-Float
99.73%
Yield 2026 *
-
Yield 2027 * -

Last Transcript : Celldex Therapeutics, Inc.

1 day-0.49%
1 week-1.56%
Current month-1.93%
1 month-9.55%
3 months+31.30%
6 months+26.47%
Current year+43.10%
1 week 38.5
Extreme 38.5
40.04
1 month 38.5
Extreme 38.5
45.14
Current year 22.33
Extreme 22.33
45.14
1 year 22.1
Extreme 22.1
45.14
3 years 14.4
Extreme 14.4
53.18
5 years 14.4
Extreme 14.4
57.2
10 years 1.5
Extreme 1.5
75.3
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 67 2014-07-29
Chief Executive Officer 64 2008-08-31
Director of Finance/CFO 55 2009-03-31
Director TitleAgeSince
Director/Board Member 64 2008-11-30
Chairman 80 2025-06-04
Director/Board Member 93 2008-02-29
Date Insider Type Main position Quantity % Market Cap. Importance
6/25/26 Free

Executive/Senior Manager

20,000 0.0255%
6/25/26 Free

Director

26,000 0.0331%
6/25/26 Free

Chief Technology Officer

57,000 0.0726%
Change 5-day change 1-year change 3-year change Capi.($)
-0.49%-1.56%+59.94%+41.17% 3.07B
-3.24%-7.78%-5.35%+10.43% 48.01B
+1.39%+0.56%+413.94%+540.11% 44.44B
-1.46%-3.11%+34.79%+18.71% 42.67B
-0.41%-3.39%-0.46%+67.04% 39.96B
0.00%-2.61%+13.09%+42.33% 32.75B
-2.47%-1.25% - - 17.74B
-1.50%-2.00%+19.68%+108.03% 16.49B
-0.37%-2.53%+10.91%+30.93% 14.38B
-1.07%-4.60%+76.86%+39.41% 13.4B
Average -0.91%-0.51%+69.27%+99.80% 27.29B
Weighted average by Cap. -0.87%-1.09%+85.15%+126.37%

Financials

2026 *2027 *
Net sales 2.03M 1.75M 1.65M 1.5M 2.81M 193M 2.82M 19.51M 7.54M 98.47M 7.63M 7.46M 312M 12.73M 10.95M 10.31M 9.4M 17.58M 1.21B 17.65M 122M 47.24M 617M 47.8M 46.76M 1.95B
Net income -319M -275M -259M -236M -441M -30.37B -443M -3.06B -1.18B -15.47B -1.2B -1.17B -49.02B -361M -311M -292M -266M -499M -34.35B -501M -3.47B -1.34B -17.5B -1.36B -1.33B -55.43B
Net Debt -662M -570M -537M -489M -915M -63.02B -919M -6.36B -2.46B -32.11B -2.49B -2.43B -102B -638M -549M -517M -471M -881M -60.67B -884M -6.12B -2.37B -30.91B -2.39B -2.34B -97.91B
Logo Celldex Therapeutics, Inc.
Celldex Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases. Its Barzolvolimab (CDX-0159) is a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is being studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis, Atopic Dermatitis and Eosinophilic Esophagitis. The Company’s bispecific platform includes CDX- 622. The CDX- 622 is a bispecific candidate for inflammatory diseases.
Employees
198
Date Price Change Volume
26-09-09 $38.87 -0.65% 226,855
26-09-08 $39.12 -1.41% 834,305
26-09-04 $39.68 +0.79% 414,532
26-09-03 $39.37 -0.28% 417,999
26-09-02 $39.48 +0.61% 476,586
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
39.12USD
Average target price
58.79USD
Spread / Average Target
+50.27%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CLDX Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!